CompoAtlas

Pure Paradise for Women

Food supplement declared in France, declaration No 2024-6-1064, decision dated 19 June 2024

Pure Paradise for Women, from Pure Paradise France, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Salvia officinalis 650 mg per day, Ocimum tenuiflorum 100 mg per day, Withania somnifera 50 mg per day. None of the rules we check flags an issue with its declared composition.

Brand
Pure Paradise
Food business operator placing the product on the market
Pure Paradise France
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
2 gélules par jour
Directions for use
Prendre 2 gélules par jour avec un verre d’eau
Intended populations
Women
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Heart problems, Liver problems, Taking medication, Prolonged use, Children (under 6), Children (under 10)

Declaration 259933, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Salvia officinalis L.FeuilleExtrait sec hydroalcoolique650 mg
Ocimum tenuiflorum L.FeuilleExtrait sec hydroalcoolique100 mg
Withania somnifera (L.) DunalRacineExtrait sec hydroalcoolique50 mg

Other ingredients

farine de riz, Gélule végétale

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Les compléments alimentaires doivent être utilisés dans le cadre d’un mode de vie sain et ne pas être utilisés comme substituts d’un régime alimentaire varié et équilibré. Tenir hors de la portée des jeunes enfants. Ne pas dépasser la dose journalière recommandée. Ne convient pas aux femmes enceintes et allaitantes, aux enfants et adolescents de moins de 18 ans, aux personnes atteintes de troubles endocriniens, hépatiques et cardiaques, aux personnes suivant un traitement ayant une action dépressive du système nerveux central. L’usage prolongé est déconseillé. A conserver à l’abri de la lumière dans un endroit frais et sec.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Salvia officinalis L.
    Read the warning, when it applies and the studies cited

    SAGE - SALVIA OFFICINALIS - Buccal

    Cautions and warnings

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.

    Health Canada monograph dated 28 March 2025

    SAGE -SALVIA OFFICINALIS Oral

    Cautions and warnings

    Condition of application: Carminative, Diaphoretic, Antihidrotic, Antigalactagogue.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Condition of application: All products.

    Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Bradley 2006; Mills and Bone 2005).

    Sources cited by Health Canada (3)
    • Bradley PR, editor. 2006: Bradley PR, editor. British Herbal Compendium Volume 2: A Handbook of Scientific Information on Widely Used Plant Drug-Companion to the British Herbal Pharmacopoeia. Bournemouth (GB): British Herbal Medicine Association; 2006.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Raton (FL): Taylor and Francis Group; 2013.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Do not use if you have a seizure disorder such as epilepsy (Gardner and McGuffin 2013; Bradley 2006; Mills and Bone 2005).

    Sources cited by Health Canada (3)
    • Bradley PR, editor. 2006: Bradley PR, editor. British Herbal Compendium Volume 2: A Handbook of Scientific Information on Widely Used Plant Drug-Companion to the British Herbal Pharmacopoeia. Bournemouth (GB): British Herbal Medicine Association; 2006.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Raton (FL): Taylor and Francis Group; 2013.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Health Canada monograph dated 10 January 2025

  • Ocimum tenuiflorum L.
    Read the warning, when it applies and the studies cited

    HOLY BASIL - OCIMUM TENUIFLORUM - SEED

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a cardiovascular condition (Rai et al. 1997; Agrawal et al. 1996).

    Sources cited by Health Canada (2)
    • Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomised trial
    • Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine. 1997;7(2):133-118. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any heart or blood pressure medication (Rai et al. 1997; Agrawal et al. 1996).

    Sources cited by Health Canada (2)
    • Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomised trial
    • Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine. 1997;7(2):133-118. PubMed

    Condition of application: Relief of cough; Digestive aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 February 2026

    HOLY BASIL - OCIMUM TENUIFLORUM - LEAF

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (WHO 2002).

    Sources cited by Health Canada (2)
    • WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CH): World Health Organization; 2002.
    • OMS 2002: Organisation mondiale de la santé (OMS). Monographs on Selected Medicinal Plants : Volume 1. Genève (CH) : Organisation mondiale de la santé; 2002.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a heart condition or diabetes (Rai et al. 1997; Agrawal et al. 1996).

    Sources cited by Health Canada (2)
    • Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomised trial
    • Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine 1997;7(2):133-118. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any heart or blood pressure medication (Rai et al. 1997; Agrawal et al. 1996).

    Sources cited by Health Canada (2)
    • Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics 1996;34(9):406-409. PubMed Randomised trial
    • Rai V, Iyer U, Mani UV. Effect of Ocimum sanctum leaf powder on blood lipoproteins, glycated proteins and total amino acids in patients with non-insulin-dependent diabetes mellitus. Journal of Nutritional and Environmental Medicine 1997;7(2):133-118. PubMed

    Condition of application: Relief of cough/cold/respiratory mucus buildup; Digestive aid; Adaptogen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Do not use if you are pregnant (Prakash et al. 2005; Ahmed et al. 2002; WHO 2002; Wohlmuth 2002; Kapoor 2001).

    Sources cited by Health Canada (6)
    • Ahmed A, Ahamed RN, Aladakatti RH, Ghoseawar MG. Reversible antifertility effect of benzene extract of Ocimum sanctum on sperm parameters and fructose content in rats. Journal of basic and clinical physiology and pharmacology 2002;13:51-59. PubMed
    • Kapoor LD. Handbook of Ayurvedic Medicinal Plants. Baton Roca (FL): CRC Press LLC; 2001.
    • Prakash P, Gupta N. Therapeutic uses of Ocimum sanctum Linn (Tulsi) with a note on eugenol and its pharmacological actions: A short review. Indian Journal of Physiology and Pharmacology 2005;49(2):125-131. PubMed Review article
    • WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CH): World Health Organization; 2002.
    • Wohlmuth H. Sacred basil - an Ayurvedic adaptogen. Botanical Pathways, 2002; Issue 11.
    • OMS 2002: Organisation mondiale de la santé (OMS). Monographs on Selected Medicinal Plants : Volume 1. Genève (CH) : Organisation mondiale de la santé; 2002.

    Health Canada monograph dated 27 February 2026

  • Withania somnifera (L.) Dunal
    Read the warning, when it applies and the studies cited

    ASHWAGANDHA - WITHANIA SOMNIFERA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).

    Sources cited by Health Canada (3)
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
    • Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).

    Sources cited by Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
    • Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.

    Health Canada monograph dated 28 February 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : Pure Paradise

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Pure Paradise for Women: composition and regulation”, https://compoatlas.com/en/supplements/products/259933-pure-paradise-for-women, updated 15 November 2026.

List recorded in 2024. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line